Amazon shares could climb 20% if the company joined healthcare industry

By Sophie Chapman
According to Simeon Siegel, a Nomura Instinet analyst, the American e-commerce retailer’s shares could gain from joining the healthcare industry. Ama...

According to Simeon Siegel, a Nomura Instinet analyst, the American e-commerce retailer’s shares could gain from joining the healthcare industry.

Amazon’s shares have already climbed 50% this year, and currently cost US$1,138.

Siegel predicts that the cost of each share would rise to $1,360 if the company entered the sector.

The company is transitioning into higher-margin products, allowing overall margins to extend, which could eventually add 1,000 basis points to gross margins.

SEE ALSO:

Another analyst, Morgan Stanley, has evaluated the multiple ways in which Amazon can enter the industry.

“Amazon’s disruption of healthcare is a foregone conclusion. Recent hires and public statements make it clear that Amazon is already moving into medical supply distribution,” wrote Mr Stanley.

“We note too that the older demographic still under-indexes toward Prime membership...which speaks to the opportunity for Pharma to help Amazon further penetrate the ~80 million 55+ population in the United States.”

“Offering this benefit of convenience will help it compete against traditional retail pharmacies and will provide yet another benefit to being a Prime member.”

Share

Featured Articles

Healthcare Business roundup: Baxter, Sanofi & Eli Lilly

Baxter International to sell kidney care spin-off Vantive; Sanofi's consumer health unit ‘to be separated’; Eli Lilly to buy Morphic Holding for $3.2bn

Trane Technologies Helping US Hospitals Meet Climate Pledge

Christy Fetsch of Trane Technologies explains how the company is helping US hospitals meet White House sustainability pledges for US healthcare provision

Nestlé Health Science Targets Weight Loss Side-Effects

Nestlé Health Science launches nutrition initiative to counteract side effects of weight-loss drugs, including hollowed-out 'Ozempic Face'

Eli Lilly Alzheimer's Drug Kisunla Approved in US by FDA

Medical Devices & Pharma

WEF: Gender Health Gap 'Costs women 75mn years of Life'

Medical Devices & Pharma

Schneider: Swathe of NHS Failing to Measure Sustainability

Sustainability